Showing 1 - 2 results of 2 for search 'Nicholas J. Izzo', query time: 0.02s Refine Results
  1. 1
    A phase 1 clinical trial of the sigma‐2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease

    A phase 1 clinical trial of the sigma‐2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease by Michael Grundman, Roger Morgan, Jason D. Lickliter, Lon S. Schneider, Steven DeKosky, Nicholas J. Izzo, Robert Guttendorf, Michelle Higgin, Julie Pribyl, Kelsie Mozzoni, Hank Safferstein, Susan M. Catalano

    Published 2019-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.

    Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. by Nicholas J Izzo, Jinbin Xu, Chenbo Zeng, Molly J Kirk, Kelsie Mozzoni, Colleen Silky, Courtney Rehak, Raymond Yurko, Gary Look, Gilbert Rishton, Hank Safferstein, Carlos Cruchaga, Alison Goate, Michael A Cahill, Ottavio Arancio, Robert H Mach, Rolf Craven, Elizabeth Head, Harry LeVine, Tara L Spires-Jones, Susan M Catalano

    Published 2014-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: